Login
$RLMD
$3.61 +$0.00 (0.0%) After hours

$RLMD SEC Filings

Filed On Filing
16 Nov 2026 8-K: Regulation FD Disclosure

Date of Report (Date of earliest event reported): November 16, 2026

12 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

12 Nov 2026 QUARTERLY REPORT
11 Sep 2026 Form 4: Shenouda Maged, Chief Financial Officer

Bought 120,200 shares ($505K) · Bought 79,800 shares ($339K)

11 Sep 2026 Form 4: Traversa Sergio, Director

Bought 100,000 shares ($418K) · Bought 100,000 shares ($410K)

08 Sep 2026 8-K: Other Events

Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology of Relmada Therapeutics, Inc., ended on September 3, 2026.

14 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.

06 Aug 2026 QUARTERLY REPORT
29 Jul 2026 SCHEDULE 13G
28 Jul 2026 8-K: Regulation FD Disclosure

Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company’s long-term growth and value creation.

22 Jun 2026 SCHEDULE 13G
18 Jun 2026 REGISTRATION STATEMENT
09 Jun 2026 SCHEDULE 13G
28 May 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Name of entity as on file with the Nevada Secretary of State : RELMADA THERAPEUTICS, INC. Entity or Nevada Business Identification Number (NVID) : NV20121345551 1. Entity information Certificate to Accompany Restated Articles or Amended ...

13 May 2026 REGISTRATION STATEMENT
13 May 2026 SCHEDULE 13G/A
12 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a dura...

12 May 2026 QUARTERLY REPORT
04 May 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support